Salvage surgery for advanced non-small cell lung cancer following previous immunotherapy: a retrospective study

Salvage surgery for advanced non-small cell lung cancer following previous immunotherapy: a retrospective study

Abstract Background The development of systemic chemotherapy including immune checkpoint inhibitors (ICIs) has provided patients with unresectable advanced non-small cell lung cancer (NSCLC) an opportunity to undergo surgical intervention after initial treatment. However, no consensus regarding the...

Full description

Bibliographic Details
Main Authors:	Mitsunori Higuchi, Sho Inomata, Hikaru Yamaguchi, Takuro Saito, Hiroyuki Suzuki
Format:	Article
Language:	English
Published:	BMC 2023-07-01
Series:	Journal of Cardiothoracic Surgery
Subjects:	Non-small cell lung cancer (NSCLC) Salvage surgery Immune checkpoint inhibitor (ICI) Downstaging Prognosis
Online Access:	https://doi.org/10.1186/s13019-023-02310-5

Similar Items

Primary versus Salvage Liver Transplantation after Curative-Intent Resection or Radiofrequency Ablation for Hepatocellular Carcinoma: Long-Term Oncological Outcomes
by: Alessandro Anselmo, et al.
Published: (2023-10-01)

Pathological Complete Response after Immune-Checkpoint Inhibitor Followed by Salvage Surgery for Clinical Stage IV Pulmonary Adenocarcinoma with Continuous Low Neutrophil-to-Lymphocyte Ratio: A Case Report
by: Mitsunori Higuchi, et al.
Published: (2021-07-01)

Potentials of Non-Invasive 18F-FDG PET/CT in Immunotherapy Prediction for Non–Small Cell Lung Cancer
by: Xuhe Liao, et al.
Published: (2022-02-01)

Case Report: Pathological Complete Response in a Brain-Metastatic Lung Squamous Cell Carcinoma Patient With Long-Term Benefit From Chemo-Immunotherapy
by: Chen Hu, et al.
Published: (2021-09-01)

Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China
by: Anwen Xiong, et al.
Published: (2021-11-01)

Liver Transplantation for Hepatocellular Carcinoma after Downstaging or Bridging Therapy with Immune Checkpoint Inhibitors
by: Qimeng Gao, et al.
Published: (2021-12-01)

The Combination of Radiotherapy With Immunotherapy and Potential Predictive Biomarkers for Treatment of Non-Small Cell Lung Cancer Patients
by: Lu Meng, et al.
Published: (2021-09-01)

The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients’ age
by: Yongfeng Wu, et al.
Published: (2020-04-01)

Dynamics of blood neutrophil‐related indices during nivolumab treatment may be associated with response to salvage chemotherapy for non‐small cell lung cancer: A hypothesis‐generating study
by: Hiroshi Soda, et al.
Published: (2019-02-01)

Addition of Salvage Immunotherapy to Targeted Therapy in Patients with Metastatic Renal Cell Carcinoma
by: Scott J. Dawsey, et al.
Published: (2021-11-01)

Retrospective (One Year) Study of Cases of Ca Cervix
by: Inder Dhir Gill, et al.
Published: (2015-07-01)

Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)
by: Wolfgang M. Brueckl, et al.
Published: (2020-12-01)

Comparison of pneumonitis risk between immunotherapy alone and in combination with chemotherapy: an observational, retrospective pharmacovigilance study
by: Huixia Li, et al.
Published: (2023-04-01)

Avoiding Absolute Quantification Trap: A Novel Predictive Signature of Clinical Benefit to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer
by: Chengming Liu, et al.
Published: (2021-11-01)

Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives
by: Luis A. Godoy, et al.
Published: (2023-01-01)

Histological Characteristics and Management of Hepatitis on Immune Checkpoint Inhibitors: A Retrospective Descriptive Study
by: Lucia Parlati, et al.
Published: (2023-05-01)

Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
by: Miriam Alonso-García, et al.
Published: (2022-04-01)

Immunotherapy Potentiates the Effect of Chemotherapy in Metastatic Melanoma—A Retrospective Study
by: Reut Hadash-Bengad, et al.
Published: (2020-02-01)

Efficacy of radiotherapy in combination with first-line immunotherapy and chemotherapy for advanced lung squamous cell carcinoma: a propensity score analysis
by: Jian Qin, et al.
Published: (2023-05-01)

The Efficacy and Safety of Neoadjuvant Immunotherapy in Patients with Non-Small Cell Lung Cancer
by: Deniz Can Guven, et al.
Published: (2023-12-01)

Impact of BMI on the survival outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis
by: Tongtong Zhang, et al.
Published: (2023-10-01)

Evaluation of Response to Immune Checkpoint Inhibitors Using a Radiomics, Lesion-Level Approach
by: Chorog Song, et al.
Published: (2021-12-01)

Editorial: CD4+ T Cells in Cancer Immunotherapies
by: José M. González-Navajas, et al.
Published: (2021-09-01)

Risk Factors, Incidence, and Prognosis of Thromboembolism in Cancer Patients Treated With Immune Checkpoint Inhibitors
by: Xue-lin Zou, et al.
Published: (2021-11-01)

Combining spatially fractionated radiation therapy (SFRT) and immunotherapy opens new rays of hope for enhancing therapeutic ratio
by: Qiuxia Lu, et al.
Published: (2024-01-01)

Predictive biomarkers of colon cancer immunotherapy: Present and future
by: Wanting Hou, et al.
Published: (2022-11-01)

Advances in immunotherapy of advanced non-small cell lung cancer with EGFR mutation
by: HUANG Huayan, et al.
Published: (2023-05-01)

Clinical significance of interstitial lung abnormalities and immune checkpoint inhibitor‐induced interstitial lung disease in patients with non‐small cell lung cancer
by: Daiki Murata, et al.
Published: (2023-01-01)

Editorial: Community series in immunotherapy with checkpoint inhibitors for non-small cell lung cancer, colon cancer, and esophageal cancer, volume II
by: Yueyi Li, et al.
Published: (2023-07-01)

The Landscape of Immunotherapy Resistance in NSCLC
by: Daniele Frisone, et al.
Published: (2022-04-01)

Optimization of the Enrichment of Circulating Tumor Cells for Downstream Phenotypic Analysis in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-1 Immunotherapy
by: Maria A Papadaki, et al.
Published: (2020-06-01)

Erratum: The landscape of immunotherapy resistance in NSCLC
by: Frontiers Production Office
Published: (2023-04-01)

Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study
by: Yi Yan, et al.
Published: (2022-04-01)

The Interplay between Anti-Angiogenics and Immunotherapy in Colorectal Cancer
by: Brigida Anna Maiorano, et al.
Published: (2022-10-01)

Progressive Sarcopenia Correlates with Poor Response and Outcome to Immune Checkpoint Inhibitor Therapy
by: Sven H. Loosen, et al.
Published: (2021-03-01)

Current status and challenges of immunotherapy in ALK rearranged NSCLC
by: Rongbin Qi, et al.
Published: (2022-12-01)

Cryotherapy for nodal metastasis in NSCLC with acquired resistance to immunotherapy
by: Lucas C. Adam, et al.
Published: (2018-12-01)

Bibliometric analysis of the 100 top-cited articles on immunotherapy of urological cancer
by: Lugeng He, et al.
Published: (2022-01-01)

Cardiac toxicity in patients with lung cancer receiving thoracic radiotherapy and immunotherapy
by: Christine Son, et al.
Published: (2023-01-01)

Rechallenge of immune checkpoint inhibitors in advanced non‐small cell lung cancer
by: Gen Lin, et al.
Published: (2024-02-01)